INmune Bio, Inc.
INMB
$1.97
-$0.01-0.28%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -55.51M | -40.80M | -42.08M | -41.27M | -37.74M |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | 21.00K | 45.00K | 79.00K | 118.00K | 157.00K |
Total Other Non-Cash Items | 23.60M | 7.90M | 7.61M | 7.73M | 7.90M |
Change in Net Operating Assets | -311.00K | 140.00K | 1.04M | 7.68M | 6.66M |
Cash from Operations | -32.20M | -32.71M | -33.36M | -25.75M | -23.03M |
Capital Expenditure | -706.00K | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -706.00K | -- | -- | -- | -- |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -5.00M | -7.50M | -10.00M | -10.00M | -10.00M |
Issuance of Common Stock | 40.26M | 33.49M | 28.21M | 27.79M | 16.27M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 35.26M | 25.99M | 18.21M | 17.79M | 6.27M |
Foreign Exchange rate Adjustments | -50.00K | 59.00K | 224.00K | -301.00K | -1.00K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 2.31M | -6.67M | -14.93M | -8.26M | -16.76M |